Latest News

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sex-based differences in neurology!

Movement disorder experts Jonathan Isaacson, MD, and Abhishek Lenka, MD, PhD, discuss early identification and accurate diagnosis of autonomic dysfunction in Parkinson disease, highlighting emerging biomarkers and monitoring tools that may enable more personalized care.

A recently published 20-year study suggests that preoperative putamen volume on MRI independently can predict motor response to GPi-DBS in patients with dystonia-dyskinesia syndrome secondary to perinatal hypoxic-ischemic encephalopathy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026.

Doris D. Wang, MD, PhD, Associate Professor of Neurological Surgery at UCSF, discusses a newly published adaptive deep brain stimulation system that adjusts in real time during walking and what it means for the future of Parkinson disease care.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Grace Gombolay, MD; and Varun Kannan, MD. [LISTEN TIME: 25 minutes]

REGENXBIO expects to resubmit the BLA for clemidsogene lanparvovec in Q3 2026 after the FDA confirmed existing CAMPSIITE data are sufficient for accelerated approval consideration.

The European Commission has approved Cenrifki (tolebrutinib) for nrSPMS without relapses in the last two years, a milestone that arrives despite the drug's failed US submission and a regulatory pathway that has been anything but linear.

A duo of neurologists discussed a new analysis suggesting that gender-affirming hormone therapy was not associated with an increased risk of seizure-related hospitalization among transgender women.

The professor of neuroscience at the University of Cambridge discussed the biology of programmed axon death, the emergence of SARM1-targeted therapies, and the challenges of translating this pathway into treatments for neurologic conditions.

Three of six patients in the first low-dose cohort achieved seizure reductions of 79% to 100% at months four through six, with no serious adverse events reported to date.

The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.